Increasing P53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3557-3564

  Guntur, Vamsi P ^a   Waldrep, J Clifford ^b   Guo, Jennifer J ^a   Selting, Kim ^c   Dhand, Rajiv ^a,d  

^a University of Missouri   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemosensitivity; Chemotherapy; Cisplatin; Lung cancer; p53; Paclitaxel

Indexed keywords

CD1 ANTIGEN; CISPLATIN; PACLITAXEL; PROTEIN P53; ANTINEOPLASTIC AGENT;

ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77958595596     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Fujita T, Kiyama M, Tomizawa Y, Kohno T and Yokota J: Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. International journal of oncology 15(5): 927-934, 1999.
2. Rom WN, Hay JG, Lee TC, Jiang Y and Tchou-Wong KM: Molecular and genetic aspects of lung cancer. Am J Resp Crit Care Med 161(4 Pt 1): 1355-1367, 2000. (Pubitemid 30243852)
3. Lai SL, Perng RP and Hwang J: p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 7(1): 64-70, 2000.
4. Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M et al: Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18(4): 1007-1014, 1999.
5. Mitsudomi T, Hamajima N, Ogawa M and Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6(70): 4055-4063, 2000.
6. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C et al: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18(4): 705-719, 2001.
7. Sigal A and Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60(24): 6788-6793, 2000.
8. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH et al: Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J NCI 91(9): 763-771, 1999.
9. Li P, Bui T, Gray D and Klamut HJ: Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53. Breast Cancer Res Treat 48(3): 273-286, 1998.
10. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T et al: Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small cell lung cancer. J Clin Oncol 24(11): 1689-1699, 2006. (Pubitemid 46622140)
11. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1): 93-101, 2003.
12. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57(19): 4285-4300, 1997.
13. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr., Kohn KW et al: An information-intensive approach to the molecular pharmacology of cancer. Science 275(5298): 343-349, 1997.
14. Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G et al: Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 55(1): 57-103, 2003. (Pubitemid 36268399)
15. Horio Y, Hasegawa Y, Sekido Y, Takahashi M, Roth JA and Shimokata K: Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther 7(4): 537-544, 2000.
16. Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H and Hara N: Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. Cancer gene therapy 7(2): 300-307, 2000.
17. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P et al: p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57(5): 870-874, 1997.
18. Yoon SS, Ahn KS, Kim SH, Shim YM and Kim J: In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype. Lung cancer (Amsterdam, Netherlands) 33(2-3): 221-228, 2001.
19. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55(21): 5038-5042, 1995.
20. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB and Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54(9): 2287-2291, 1994. (Pubitemid 24138709)
21. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M et al: p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 89(4): 769-773, 2000.
22. Hawkins DS, Demers GW and Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56(4): 892-898, 1996.
23. 2/M accumulation. Int J Radia7t Oncol Biol Phys 44(5): 1119-1124, 1999.
24. 2/M arrest and apoptosis. Nature Med 2(1): 72-79, 1996.
25. Ling YH, Zou Y and Perez-Soler R: Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells. Anticancer Res 20(2A): 693-702, 2000.
26. Inoue A, Narumi K, Matsubara N, Sugawara S, Saijo Y, Satoh K et al: Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anticancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett 157(1): 105-112, 2000.
27. Nielsen LL, Lipari P, Dell J, Gurnani M and Hajian G: Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4(4): 835-846, 1998. (Pubitemid 28183383)
28. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B et al: Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 3(6): 632-638, 1997.
29. Wieczorek AM, Waterman JL, Waterman MJ and Halazonetis TD: Structure-based rescue of common tumor-derived p53 mutants. Nature medicine 2(10): 1143-1146, 1996.
30. Deng WG, Wu G, Ueda K, Xu K, Roth JA and Ji L: Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Cancer Gene Ther 15(1): 29-39, 2008.
31. Fung YK: inventor Mutants of the Rb and p53 genes and uses thereof. U.S. patent 6590086. 8 July 2003, 2003.
32. Densmore CL, Orson FM, Xu B, Kinsey BM, Waldrep JC, Hua P et ah Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther 1(2): 180-188, 2000.
33. Gautam A, Densmore CL, Xu B and Waldrep JC: Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol Ther 2(1): 63-70, 2000.
34. Gautam A, Densmore CL and Waldrep JC: Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes. Mol Ther 2(4): 318-323, 2000.
35. Vogt U, Zaczek A, Klinke F, Granetzny A, Bielawski K and Falkiewicz B: p53 Gene Status in relation to ex vivo chemosensitivity of non-small cell lung cancer. J Cancer Res Clin Oncol 128(3): 141-147, 2002. (Pubitemid 34185636)
36. Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zochbauer-Muller S, Kuhrer I et al: Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thorac Cardiovasc Surg 135(5): 1036-1041, 2008.
37. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A et al: Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6(12): 4932-4938, 2000.
38. Rosell R, Gonzalez-Larriba JL, Alberola V, Molina F, Monzo M, Benito D et al: Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Sem Oncol 22(6 Suppl 14): 12-18, 1995.
39. O'Connor DS, Wall NR, Porter AC and Altieri DC: A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2(1): 43-54, 2002.
40. Woods CM, Zhu J, McQueney PA, Bollag D and Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1(5): 506-526, 1995.
41. Blagosklonny MV: Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6(1): 70-74, 2007.
42. Blagosklonny MV, Robey R, Sheikh MS and Fojo T: Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. Cancer Biol Ther 1(2): 113-117, 2002.
43. Fulda S, Meyer E and Debatin KM: Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 60(14): 3947-3956, 2000. (Pubitemid 32204591)
44. Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY et al: Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 63(3): 621-626, 2003.
45. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78(4): 539-542, 1994.
46. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupoid SE, Forrester K et al: The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 10(10): 1219-1232, 1996.
47. Tsai CM, Chang KT, Li L, Perng RP and Yang LY: Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 91(2): 213-222, 2000.
48. Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N et al: Molecular predictors of response to chemotherapy in lung cancer. Sem Oncology 31(1 Suppl 1): 20-27, 2004.